Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891745 | 0.81 | LMNA (0.36) | CNR2GRIA2 | |
| SCHEMBL16480371 | 0.80 | PTGS2 (0.47) | CNR2PTGS2PTGS1GPR119HSD11B1 | |
| SCHEMBL9891746 | 0.80 | CNR2 (0.45) | CNR2PTGS2HSD11B1CYP1A2 | |
| SCHEMBL9891736 | 0.80 | ALDH1A1 (0.41) | HDAC1HDAC8HDAC6 | |
| SCHEMBL9891734 | 0.78 | CRHBP (0.43) | — | |
| SCHEMBL9891747 | 0.78 | CNR2 (0.47) | CNR2HDAC1HDAC8HDAC6 | |
| SCHEMBL9891743 | 0.78 | PTGER2 (0.36) | CNR2HDAC1HDAC8HDAC6 | |
| SCHEMBL9892982 | 0.77 | PTGS2 (0.44) | CNR2PTGS2PTGS1GPR119HSD11B1 | |
| SCHEMBL9891733 | 0.77 | CNR2 (0.47) | CNR2 | |
| SCHEMBL9104782 | 0.75 | CNR2 (0.55) | CNR2PTGS2PTGS1GPR119HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885PTGS2 240/4885PTGS1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.